How Will uniQure NV (NASDAQ:QURE) Stock React To New Rating Coverage bySunTrust Robinson?

May 24, 2018 - By Linda Rogers

uniQure N.V. (NASDAQ:QURE) Logo

Why Has SunTrust Robinson Given uniQure NV (NASDAQ:QURE) a $48.0000 Price Target

Analysts at SunTrust Robinson has begun coverage on shares of uniQure NV (NASDAQ:QURE) in a note issued to clients and investors on Thursday morning. The firm set “Buy” rating on the $1.29B market cap company.

uniQure N.V. (NASDAQ:QURE) Ratings Coverage

Among 5 analysts covering uniQure NV (NASDAQ:QURE), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. uniQure NV has $6300 highest and $25.0 lowest target. $45’s average target is 29.16% above currents $34.84 stock price. uniQure NV had 7 analyst reports since December 1, 2017 according to SRatingsIntel. Janney Capital maintained uniQure N.V. (NASDAQ:QURE) on Tuesday, March 20 with “Buy” rating. Wells Fargo initiated it with “Buy” rating and $4700 target in Wednesday, May 16 report. The company was maintained on Monday, May 7 by Leerink Swann. On Wednesday, May 23 the stock rating was maintained by Chardan Capital Markets with “Buy”. The rating was maintained by H.C. Wainwright with “Buy” on Thursday, March 15. The stock has “Buy” rating by Janney Capital on Wednesday, January 3.

The stock increased 6.04% or $1.99 during the last trading session, reaching $34.84. About 455,331 shares traded or 16.86% up from the average. uniQure N.V. (NASDAQ:QURE) has risen 293.97% since May 24, 2017 and is uptrending. It has outperformed by 282.42% the S&P500.

Analysts await uniQure N.V. (NASDAQ:QURE) to report earnings on August, 14. They expect $-0.68 EPS, up 18.07 % or $0.15 from last year’s $-0.83 per share. After $-0.59 actual EPS reported by uniQure N.V. for the previous quarter, Wall Street now forecasts 15.25 % negative EPS growth.

uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company has market cap of $1.29 billion. The companyÂ’s principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease. It currently has negative earnings. It also provides Glybera, a gene therapy product that has approved for the treatment of patients with lipoprotein lipase deficiency.

More notable recent uniQure N.V. (NASDAQ:QURE) news were published by: Globenewswire.com which released: “uniQure Announces to Present at Multiple Conferences in May” on April 27, 2018, also Streetinsider.com with their article: “uniQure (QURE) Highlights New Data from Phase I/II Clinical trial of AMT-060 Showing Successful Liver Transduction …” published on May 21, 2018, Globenewswire.com published: “uniQure Announces Proposed Public Offering” on May 01, 2018. More interesting news about uniQure N.V. (NASDAQ:QURE) were released by: Benzinga.com and their article: “Uniqure Notches Bullish Initiation On Gene Therapy Prospects” published on May 20, 2018 as well as Nasdaq.com‘s news article titled: “uniQure Presents New Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Anti-AAV5 …” with publication date: May 21, 2018.

uniQure N.V. (NASDAQ:QURE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.